



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** pNL4-3.HSA.R+E-

**Catalog Number:** 3420

**Lot Number:** 99516

**Release Category:** C

**Provided:** 1 vial ampicillin-resistant, transformed STBL2 cells (Gibco-BRL).

**Cloning Vector:** pUC-19.

**Description:** Env- due to a 5' frameshift. Competent for a single round of replication. Requires cotransfection with env expression vector to produce infectious virus.

**Special Characteristics:** Murine heat stable antigen CD24 (HSA) gene was inserted into the pNL4-3 nef gene. Virus can be produced by transfecting  $2 \times 10^6$  293 or 293T cells with 10  $\mu$ g NL4-3 DNA and 10  $\mu$ g env expression vector DNA. Transfections can be performed in a 10 cm<sup>2</sup> tissue culture dish using standard calcium phosphate protocols. Virus is typically harvested 48 hours post-transfection. Infections should be performed in a total volume of 0.5 ml. The amphotropic pseudotypes generally have much higher infectivity than those bearing HIV-1 env. Cultures infected with HSA viruses can be assayed by FACS analysis with a commercial CD24 antibody (Pharmingen) 2-5 days post-infection.

[Plasmid Map](#)

**Recommended Storage:** -70°C.

**Contributor:** Dr. Nathaniel Landau, Aaron Diamond AIDS Research Center, The Rockefeller University.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**References:** He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34<sup>cdc2</sup> activity. *J Virol* **69**:6705-6711, 1995. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. *Virology* **206**:935-944, 1995.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3.HSA.R+.E- from Dr. Nathaniel Landau." Also include the references cited above in any publications. Patent pending.

**Last Updated** November 30, 2015

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.